Evidence map›Paper›PMID 41794844›Full record

Trial reportNature communications2026

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.

Daniel J Renouf, James T Topham, Jonathan M Loree, David F Schaeffer, Jennifer J Knox, Petr Kavan, Derek Jonker, Stephen Welch, Felix Couture, Frederic Lemay and 14 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Daniel J RenoufPancreas Centre BC, Vancouver, BC, Canada. drenouf@bccancer.bc.ca.ORCID http://orcid.org/0000-0002-7597-6089
James T TophamPancreas Centre BC, Vancouver, BC, Canada.
Jonathan M LoreeDivision of Medical Oncology, BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-8189-2132
David F SchaefferDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Jennifer J KnoxDivision of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada.ORCID http://orcid.org/0000-0003-3474-6647
Petr KavanDepartments of Oncology and Medical Oncology, Sir Mortimer B. Davis Jewish General Hospital, Segal Cancer Centre, McGill University, Montreal, QC, Canada.
Derek JonkerThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Stephen WelchLondon Regional Cancer Program, London, ON, Canada.
Felix CoutureCHU de Quebec Research Centre and Faculty of Medicine, Laval University, Quebec City, QC, Canada.
Frederic LemayFaculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, Canada.
Mustapha TehfeHematology and Medical Oncology Service, Centre Hospitalier Universitaire de Montreal, University of Montreal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-1380-5110
Mohammed HarbThe Moncton City Hospital, Moncton, NB, Canada.
Nathalie AucoinHopital Cite-de-la-Sante, Laval, QC, Canada.
Yoo-Joung KoDepartment of Medicine, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Patricia A TangArthur J.E. Child Comprehensive Cancer Centre and University of Calgary, Calgary, AB, Canada.
Ravi RamjeesinghDivision of Medical Oncology, QEII Health Sciences Centre, Halifax, NS, Canada.ORCID http://orcid.org/0000-0001-5584-3505
Brandon M MeyersJuravinski Cancer Centre, Hamilton, ON, Canada.
Christina A KimCancerCare Manitoba, Winnipeg, MN, Canada.ORCID http://orcid.org/0000-0003-3847-2583
Pan DuPredicine Inc., Hayward, California, USA.
Shidong JiaPredicine Inc., Hayward, California, USA.
Joanna M KarasinskaPancreas Centre BC, Vancouver, BC, Canada.
Sharlene GillDivision of Medical Oncology, BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0003-3306-3617
Dongsheng TuCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.ORCID http://orcid.org/0000-0003-4842-2184
Chris J O'CallaghanCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.

Funding

Canadian Cancer Society Research Institute (Société Canadienne du Cancer) 707213
6 · The paper itself

Abstract

The CCTG PA.7 study was a randomized phase II trial comparing chemotherapy with and without dual immune checkpoint inhibition in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In follow-up to the published primary results of the trial, the analysis herein focused on long-term survival and exploratory analysis.Plasma sequencing analysis identified concurrent mutations in DNA damage repair genes BRCA1, POLE, ATM and FANCA in 18/173 (10.40%) of patients, and presence of two or more mutations in these genes was associated with overall survival benefit for patients receiving immunotherapy (median overall survival 26.2 vs. 9.7 months; hazard ratio, 0.34; 95% CI, 0.16-0.68; p = 0.001; interaction p = 0.003). Partial response was observed in 7/11 (63.64%) patients with concurrent DNA damage repair gene mutations in the immunotherapy arm. As a prospective study in PDAC identifying a potential biomarker beyond mismatch repair deficiency for benefit from immunotherapy, these data highlight an actionable subgroup of mPDAC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalDNA RepairPancreatic NeoplasmsAgedAlbuminsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDeoxycytidineFemaleGemcitabineHumansMaleMiddle AgedMutationPaclitaxel130-nm albumin-bound paclitaxelAlbuminsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDeoxycytidinedurvalumabGemcitabinePaclitaxel

Identifiers

PMID41794844
PMCPMC13096329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.